Dr Andrew Durham is a Research Fellow in the Airway Disease section of the National Heart and Lung Institute (NHLI) at Imperial College London. His research is focused on identifying the molecular and epigenetic mechanisms which drive remodeling in chronic lung diseases including asthma and chronic obstructive pulmonary disease (COPD). Dr Durham graduated from the University of Nottingham with a BSc in Genetics. He continued his studies at Imperial College London where he obtained an MSc. (with distinction) in the Molecular Biology and Pathology of Viruses and subsequently a PhD in Microbiology. After a gap year travelling, Dr Durham changed disciplines to human respiratory diseases and joined Professor Adcock's Molecular Cell Biology group. Initially working with on several clinical trials, including investigating the efficacy of low dose theophylline in restoring steroid sensitivity in COPD patients, Dr Durham has continued to develop his own research, focused on the molecular and epigenetic mechanisms involved in remodeling in chronic lung diseases, such as asthma and COPD. Dr Durham's current work is primarily focused on investigating the epigenetic regulation of gene expression and cell fate, including how environmental factors such as cigarette smoking, drive these epigenetic changes. In addition to his research work, Dr Durham is involved in undergraduate teaching and personal tutoring to both Medical and Biomedical sciences students. He also supervises several undergraduate and postgraduate research students, from BSc to PhD level.

lung diseases , EPIGENETICS